Infectious complications of CD19-targeted chimeric antigen receptor–modified T-cell immunotherapy

Turtle, 2016, CD19-Targeted chimeric antigen receptor-modified T-cell immunotherapy for B-cell malignancies, Clin Pharmacol Ther, 100, 252, 10.1002/cpt.392

Frey, 2016, The promise of chimeric antigen receptor T-cell therapy, Oncology (Williston Park), 30, 880

Kenderian, 2017, Chimeric antigen receptor T cells and hematopoietic cell transplantation: how not to put the CART before the horse, Biol Blood Marrow Transplant, 23, 235, 10.1016/j.bbmt.2016.09.002

Turtle, 2016, Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells, Sci Transl Med, 8, 355ra116, 10.1126/scitranslmed.aaf8621

Turtle, 2016, CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients, J Clin Invest, 126, 2123, 10.1172/JCI85309

Maude, 2014, Chimeric antigen receptor T cells for sustained remissions in leukemia, N Engl J Med, 371, 1507, 10.1056/NEJMoa1407222

Kochenderfer, 2012, B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells, Blood, 119, 2709, 10.1182/blood-2011-10-384388

Porter, 2011, Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia, N Engl J Med, 365, 725, 10.1056/NEJMoa1103849

Lee, 2015, T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial, Lancet, 385, 517, 10.1016/S0140-6736(14)61403-3

Porter, 2015, Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia, Sci Transl Med, 7, 303ra139, 10.1126/scitranslmed.aac5415

Davila, 2014, Sci Transl Med

Turtle, 2017, J Clin Oncol

Brudno, 2016, Toxicities of chimeric antigen receptor T cells: recognition and management, Blood, 127, 3321, 10.1182/blood-2016-04-703751

Lee, 2014, Current concepts in the diagnosis and management of cytokine release syndrome, Blood, 124, 188, 10.1182/blood-2014-05-552729

Navarro, 2014, Tocilizumab in rheumatoid arthritis: a meta-analysis of efficacy and selected clinical conundrums, Semin Arthritis Rheum, 43, 458, 10.1016/j.semarthrit.2013.08.001

De Pauw, 2008, Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group, Clin Infect Dis, 46, 1813, 10.1086/588660

van Burik, 2007, Biol Blood Marrow Transplant

Young, 2016, Infections after transplantation of bone marrow or peripheral blood stem cells from unrelated donors, Biol Blood Marrow Transplant, 22, 359, 10.1016/j.bbmt.2015.09.013

Martin, 1996, Exact estimates for a rate ratio, Epidemiology, 7, 29, 10.1097/00001648-199601000-00006

Hay, Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor–modified T-cell therapy, Blood

Kantarjian, 2017, Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia, N Engl J Med, 376, 836, 10.1056/NEJMoa1609783

Gisselbrecht, 2010, Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era, J Clin Oncol, 28, 4184, 10.1200/JCO.2010.28.1618

Hallek, 2010, Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial, Lancet, 376, 1164, 10.1016/S0140-6736(10)61381-5

Freifeld, 2011, Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America, Clin Infect Dis, 52, e56, 10.1093/cid/cir073

Fishman, 1998, Infection in organ-transplant recipients, N Engl J Med, 338, 1741, 10.1056/NEJM199806113382407

Tomblyn, 2009, Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective, Biol Blood Marrow Transplant, 15, 1143, 10.1016/j.bbmt.2009.06.019

Marr, 2000, Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial, Blood, 96, 2055, 10.1182/blood.V96.6.2055

Ullmann, 2007, Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease, N Engl J Med, 356, 335, 10.1056/NEJMoa061098